Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada-Reference-Cited by-同舟云学术

Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada

Published:2022-12-18 Issue:2 Volume:29 Page:488-497
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Yu Jacky K.¹,Wong William W. L.¹,Keepanasseril Arun²,Iorio Alfonso²³,Edginton Andrea N.¹

Affiliation:

1. School of Pharmacy University of Waterloo Waterloo Ontario Canada

2. Department of Health Research Methods Evidence and Impact McMaster University Ontario Canada

3. McMaster‐Bayer Endowed Research Chair for Clinical Epidemiology of Congenital Bleeding Disorders Department of Medicine McMaster University Ontario Canada

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14723

Reference41 articles.

1. Clotting factor concentrates given to prevent bleeding and bleeding‐related complications in people with hemophilia A or B;Iorio A;Cochrane Database Syst Rev,2011

2. Clotting factor concentrate switching and inhibitor development in hemophilia A

3. Emerging drugs for the treatment of hemophilia A and B

4. Targeting anticoagulant protein S to improve hemostasis in hemophilia

5. Physicians’ perceptions of adherence to prophylactic clotting factor infusions

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab as a Promising Form of Therapy for Type A Hemophilia - AReview of Current Knowledge from Clinical Trials;Current Protein & Peptide Science;2024-11

2. Can German Health Insurance Claims Data Fill Information Gaps in Rare Chronic Diseases: Use Case of Haemophilia A;Hämostaseologie;2024-07-01

3. Cost‐effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States;American Journal of Hematology;2023-07-04